Not finding it? Sign in to also search OpenAlex live.
-
Randomized Trial Comparing 5-Year Follow-Up of First-Line Infliximab to Conventional Therapy in Pediatric Crohn’s Disease2026 Clinical Gastroenterology and Hepatology article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Stephanie A. Vuijk, M.M.E. Jongsma, M.A. Cozijnsen, Merel van Pieterson, T.G.J. de Meij, M. Groeneweg, +15 more
1citations -
Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study
Steffen Koschmieder, Eyck von der Heyde, Lambert Busque, Françoise Boyer‐Perrard, Timothy Devos, Francesco Passamonti, +9 more
1citations -
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)
Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, Patrick Schöffski, Yann Godbert, Patrice Rodien, +14 more
8citations -
Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization2024 Frontiers in Radiology article Medicine Hepatocellular Carcinoma Treatment and Prognosis Open access
Julia Wagenpfeil, Patrick Arthur Kupczyk, Philipp Bruners, Robert Malte Siepmann, Emelie Guendel, Julian Alexander Luetkens, +6 more
5citations -
Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial
Anna Stoelinga, Maarten E. Tushuizen, Wilbert B. van den Hout, Mar D. M. Rodriguez Girondo, Elsemieke S. de Vries, Amar D. Levens, +15 more
11citations -
Long-term quality of life in patients with metastatic esophagogastric cancer receiving first-line systemic therapy.2023 Journal of Clinical Oncology conference-abstract Medicine Gastric Cancer Management and Outcomes Open access
Marieke Pape, Pauline A. J. Vissers, Marije Slingerland, Nadia Haj Mohammad, Lonneke Veronique van de Poll-Franse, Rob H.A. Verhoeven, +1 more
1citations -
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations2020 The European Journal of Health Economics article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access
Lotte Westerink, Jelmer Lennart Jens Nicolai, Carl Haakon Samuelsen, Hans J.M. Smit, Pieter E. Postmus, Ingolf Griebsch, +1 more
10citations -
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study2025 Therapeutic Advances in Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Steffen Koschmieder, Eyck von der Heyde, Lambert Busque, Françoise Boyer‐Perrard, Timothy Devos, Francesco Passamonti, +5 more
1citations -
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)
Wing Hee Fung, Mark HJ Wessels, Eline M. E. Coerver, Janet de Beukelaar, Willem H. Bouvy, Leo R. Canta, +23 more
4citations -
Abstract PO1-04-12: Palbociclib versus ribociclib in first-line treatment of patients with hormone-receptor positive HER2 negative advanced breast cancer – real world outcome data from the German registry platform OPAL
Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Matthias R. Zaiss, Kathrin Engelken, +11 more
7citations -
KEYMAKER-U01J: Calderasib plus pembrolizumab with or without cetuximab as first-line treatment for advanced or metastatic nonsquamous non–small-cell lung cancer (NSCLC) with KRAS G12C mutations.2026 Journal of Clinical Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations Open access
Qing Zhou, Daniel Almquist, B K Cho, Egbert Frederik Smit, Christian Caglevic, Ilkka Liikanen, +13 more
0citations